Acceleration of restenosis by diabetes: Pathogenetic implications

Circulation

Volumn 103, Issue 9, 2001, Pages 1185-1187

  Sobel, Burton E ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Acute coronary syndromes; Coronary interventions; Editorials; Stents

Indexed keywords

ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ANGIOGRAPHY; DIABETES MELLITUS; DISEASE SEVERITY; EDITORIAL; HEART MUSCLE REVASCULARIZATION; LONG TERM CARE; MORTALITY; PATHOGENESIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; TREATMENT OUTCOME;

EID: 0035814956     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.9.1185     Document Type: Editorial

References (34)

1. Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: A key determinant of survival in diabetics after coronary balloon angioplasty
2. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease
3. Eight year mortality in the Emory Angioplasty vs Surgery Trial (EAST)
4. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty
5. Relationship between diabetes mellitus and long-term survival after coronary bypass angioplasty
6. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus
7. Does stenting prevent diabetic arterial shrinkage after percutaneous coronary revascularization?
8. Enhanced secretion of insulin plays a role in the development of atherosclerosis and restenosis of coronary arteries: Elective percutaneous transluminal coronary angioplasty in patients with effort angina
9. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
10. Troglitazone reduces intimal hyperplasia after coronary stent implantation in patients with type 2 diabetes mellitus: A serial intravascular ultrasound study
11. Hyperinsulinemia as an independent risk factor for ischemic heart disease
12. Cardiovascular consequences of PCOS
13. Role of insulin resistance in human disease
14. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial
15. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes
16. Thromboxane biosynthesis and platelet function in type II diabetes mellitus
17. Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients
18. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects
19. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients
20. The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes
21. Neointima formation after vascular stent implantation: Spatial and chronological distribution of smooth muscle cell proliferation and phenotypic modulation
22. Paradoxic decreases in atherosclerotic plaque mass in insulin-treated diabetic patients
23. Tissue characteristics of restenosis after percutaneous transluminal coronary angioplasty in diabetic patients
24. Increased plasminogen activator inhibitor-1 and vasculopathy: A reconcilable paradox
25. Molecular basis of the acute coronary syndromes
26. Plaque rupture with severe preexisting stenosis precipitating thrombosis: Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi
27. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: A potential factor predisposing to thrombosis and its persistence
28. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
29. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes mellitus and in lean and obese normal subjects
30. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects
31. Potassium, glucose and insulin in myocardial infarction
32. Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion
33. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction